Medical Mycology 2007-06-01

Evaluation of combined deactivators-supplemented agar medium (CDSAM) for recovery of dermatophytes from patients with tinea pedis.

Makoto Adachi, Shinichi Watanabe

Index: Med. Mycol 45(4) , 347-9, (2007)

Full Text: HTML

Abstract

Using a newly-developed medium, i.e., combined deactivators-supplemented agar medium (CDSAM), the viability of dermatophytes in skin scales was evaluated. Culture studies were conducted with skin scales collected from 44 patients with tinea pedis who had been treated for two weeks with topical antifungal drugs. Sixty-four percent of the specimens were mycologically positive on CDSAM, while only 23% of these same specimens were positive when cultured on conventional Sabouraud's dextrose agar medium (SDA). Alternatively, 36% of all cases were negative on both media. The experimental data from this clinical study indicate that CDSAM was more useful than SDA in accurately evaluating the efficacy of antifungal drugs since the former minimized the residual effects of drug residues remaining in the skin samples.

Related Compounds

  • Sisomycin Sulfate

Related Articles:

Determination of equilibrium constant of amino carbamate adduct formation in sisomicin by a high pH based high performance liquid chromatography.

2015-01-01

[J. Pharm. Biomed. Anal. 111 , 126-30, (2015)]

Biomimetic synthesis and structural refinement of the macrocyclic dimer aminoglycoside 66-40C--the remarkably selective self-condensation of a putative aldehyde intermediate in the submerged culture medium producing sisomicin.

2010-03-28

[Chem. Commun. (Camb.) 46(12) , 2013-5, (2010)]

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.

2011-12-01

[Antimicrob. Agents Chemother. 55(12) , 5874-80, (2011)]

Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals.

2011-10-01

[Int. J. Antimicrob. Agents 38(4) , 352-4, (2011)]

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City.

2010-10-01

[J. Antimicrob. Chemother. 65(10) , 2123-7, (2010)]

More Articles...